Targeted cancer therapy with a 2-deoxyglucose-based adriamycin complex

Cancer Research

Volumn 73, Issue 4, 2013, Pages 1362-1373

  Cao, Jie ^a   Cui, Sisi ^a   Li, Siwen ^a   Du, Changli ^a   Tian, Junmei ^a   Wan, Shunan ^a   Qian, Zhiyu ^a,b   Gu, Yueqing ^a   Chen, Wei R ^c   Wang, Guangji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF AERONAUTICS AND ASTRONAUTICS   (China)

^c UNIVERSITY OF CENTRAL OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 CARBOXYL 1 OXOPROPYL) AMINO 2 DEOXY DEXTRO GLUCOSE ADRIAMYCIN; ANTINEOPLASTIC AGENT; DOXORUBICIN; GLUCOSE TRANSPORTER 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TARGETING; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MOUSE; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DEOXYGLUCOSE; DOXORUBICIN; GLUCOSE TRANSPORTER TYPE 1; HEP G2 CELLS; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; MODELS, CHEMICAL; MOLECULAR STRUCTURE; NEOPLASMS; QUERCETIN; SUCCINIC ACID; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874316302     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2072     Document Type: Article

References (38)

1. Emmenegger U, Kerbel RS. Cancer: chemotherapy counteracted. Nature 2010;468:637-8.
2. Bildstein L, Dubernet C, Couvreur P. Prodrug-based intracellular delivery of anticancer agents. Adv Drug Deliv Rev 2011;63:3-23.
3. Nussbaumer S, Bonnabry P, Veuthey JL, Fleury-Souverain S. Analysis of anticancer drugs: a review. Talanta 2011;85:2265-89.
4. Perrino C, Schiattarella GG, Magliulo F, IIardi F, Carotenuto G, Gargiulo G, et al. Cardiac side effects of chemotherapy: state of art and strategies for a correct management. Curr Vasc Pharmacol. 2012 May 8. PMID:22563720.
5. Kim JH, Sung NY, Raghavendran H, Yoon Y, Song BS, Choi J. Gamma irradiation reduces the immunological toxicity of doxorubicin, anticancer drug. Radiat Phys Chem 2009;78:425-28.
6. Raschi E, Vasina V, Ursino MG, Boriani G, Martoni A, De Ponti F. Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther 2010;125:196-218.
7. Pathania D, Millard M, Neamati N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Deliv Rev 2009;61:1250-75.
8. Kievit FM, Wang FY, Fang C, Mok H, Wang K, Silber JR, et al. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J Control Release 2011;152:76-83.
9. Zhang H, Li F, Yi J, Gu C, Fan L, Qiao Y, et al. Folate-decorated maleilated pullulan-doxorubicin conjugate for active tumor-targeted drug delivery. Eur J Pharm Sci 2011;42:517-26.
10. Zheng C, Xu J, Yao X, Qiu L. Polyphosphazene nanoparticles for cytoplasmic release of doxorubicin with improved cytotoxicity against Dox-resistant tumor cells. J Colloid Interface Sci 2011;355:374-82.
11. Cho HJ, Yoon IS, Yoon HY, Koo H, Jin YJ, Ko SH, et al. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Biomaterials 2012;33: 1190-200.
12. Ogawara K, Un K, Tanaka K, Higaki K, Kimura T. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumorbearing mice: involvement of cytotoxic effect on vascular endothelial cells. J Control Release 2009;133:4-10.
13. Hu Z, Jiang X, Albright CF, Graciani N, Yue E, Zhang M, et al. Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents. Bioorg Med Chem Lett 2010; 20:853-6.
14. Mahato R, Tai W, Cheng K. Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev 2011;63:659-70.
15. Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010;467:543-9.
16. Stepankova J, Studenovsky M, Malina J, Kasparkova J, Liskova B, Novakova O, et al. DNA interactions of 2-pyrrolinodoxorubicin, a distinctively more potent daunosamine-modified analogue of doxorubicin. Biochem Pharmacol 2011;82:227-35.
17. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
18. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 2009;121:29-40.
19. Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol Rev 1994;74:993-1026. (Pubitemid 24328943)
20. Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, et al. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol 2009;174: 1544-52.
21. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR. 2-Deoxy- D-glucose combinedwith cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 2007;67:3364-70. (Pubitemid 46724876)
22. Mohanti BK, Rath GK, Anantha N, Kannan V, Das BS, Chandramouli BA, et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 1996;35:103-11. (Pubitemid 26137174)
23. Simons AL, Fath MA, Mattson DM, Smith BJ, Walsh SA, Graham MM, et al. Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging. Int J Radiat Oncol Biol Phys 2007;69:1222-30. (Pubitemid 47625869)
24. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, et al. 2-Deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004;64:31-4.
25. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2- fluoro-D-glucose. J Nucl Med 1978;19:1154-61. (Pubitemid 9059983)
26. Yalcin A, Telang S, Clem B, Chesney J. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol 2009;86:174-9.
27. Song YS, Lee WW, Chung JH, Park SY, Kim YK, Kim SE. Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer 2008;61:54-60.
28. van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007;43:1392-8.
29. Suzuki H, Fukuyama R, Hasegawa Y, Tamaki T, Nishio M, Nakashima T, et al. Tumor thickness, depth of invasion, and Bcl-2 expression are correlated with FDG-uptake in oral squamous cell carcinomas. Oral Oncol 2009;45:891-7.
30. Daumar P, Decombat C, Chezal JM, Debiton E, Madesclaire M, Coudert P, et al. Design, synthesis and in vitro drug release investigation of new potential 5-FU prodrugs. Eur J Med Chem 2011;46: 2867-79.
31. Reux B, Weber V, Galmier MJ, Borel M, Madesclaire M, Madelmont JC, et al. Synthesis and cytotoxic properties of new fluorodeoxyglucosecoupled chlorambucil derivatives. Bioorg Med Chem 2008;16: 5004-20. (Pubitemid 351635770)
32. Miot-Noirault E, Reux B, Debiton E, Madelmont JC, Chezal JM, Coudert P, et al. Preclinical investigation of tolerance and antitumour activity of new fluorodeoxyglucose-coupled chlorambucil alkylating agents. Invest New Drugs 2011;29:424-33.
33. Zhang J, Chen H, Xu L, Gu Y. The targeted behavior of thermally responsive nanohydrogel evaluated by NIR system in mouse model. J Control Release 2008;131:34-40.
34. Shan L, Cui S, Du C, Wan S, Qian Z, Achilefu S, et al. A paclitaxelconjugated adenovirus vector for targeted drug delivery for tumor therapy. Biomaterials 2012;33:146-62.
35. Vera JC, ReyesAM, Vel-asquez FV, Rivas CI, Zhang RH, Strobel P, et al. Direct inhibition of the hexose transporter GLUT1 by tyrosine kinase inhibitors. Biochemistry 2001;40:777-90. (Pubitemid 32096863)
36. Tang XH, Xie P, Ding Y, Chu LY, Hou JP, Yang JL, et al. Synthesis, characterization, and in vitro and in vivo evaluation of a novel pectinadriamycin conjugate. Bioorg Med Chem 2010;18:1599-609.
37. Guo J, Du C, Shan L, Zhu H, Xue B, Qian Z, et al. Comparison of near-infrared fluorescent deoxyglucose probes with different dyes for tumor diagnosis in vivo. Contrast Media Mol Imaging 2012; 7:289-301.
38. Wang F, Wang YC, Dou S, Xiong MH, Sun TM, Wang J. Doxorubicintethered reponsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 2011;5:3679-92.